

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68		A1	(11) International Publication Number: WO 00/47767
			(43) International Publication Date: 17 August 2000 (17.08.00)
(21) International Application Number: PCT/GB00/00357		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 8 February 2000 (08.02.00)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 9902970.4 11 February 1999 (11.02.99) GB			
(71) Applicant (for all designated States except US): AS-TRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): LITTLE, Stephen [GB/GB]; Gadbrook Park, Northwich, Cheshire CW9 7RA (GB). GIBSON, Neil, James [GB/GB]; Gadbrook Park, Northwich, Cheshire CW9 7RA (GB). WHITCOMBE, David, Mark [GB/GB]; Gadbrook Park, Northwich, Cheshire CW9 7RA (GB).			
(74) Agent: BILL, Kevin; Global Intellectual Property, AstraZeneca UK Limited, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).			
(54) Title: OLIGONUCLEOTIDE ARRAY AND METHODS OF USE			
(57) Abstract <p>The present invention is directed to an oligonucleotide array ("generic" array) consisting of a plurality of different oligonucleotides of predetermined sequence, attached to a solid surface at predetermined positionally distinct locations, characterised in that the oligonucleotides have substantially the same melting temperature (T_m) and to methods utilising said "generic" array.</p>			

ATTORNEY DOCKET NUMBER: 9301-123
SERIAL NUMBER: 09/724,538
REFERENCE: CD

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Cote d'Ivoire	KM	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

5

10

15

20

25

30

35

40

45

50

55

OLIGONUCLEOTIDE ARRAY AND METHODS OF USE

5
10 The present invention is directed to an oligonucleotide array ('generic' array) consisting of a plurality of different oligonucleotides of predetermined sequence, attached to a
15 solid surface at predetermined positionally distinct locations, characterised in that the oligonucleotides have substantially the same melting temperature (T_m). The invention is also directed to probe and primer targeting polynucleotides which contain nucleotide sequences
20 that are complementary to different target nucleic acids from a test sample as well as to the oligonucleotides on the array. The 'generic' array and targeting oligonucleotides prove
10 useful in a number of hybridisation capture methods and assays such as, sequence identification by allele specific hybridisation, fingerprinting and genome typing, differential
25 gene expression profile analysis, or in clinical diagnostic methods utilising for example, ARMS amplification primers. The present invention is therefore also directed to methods or assays utilising such 'generic' arrays and, in particular, to the use of a multiplex amplification
15 assay that utilises a plurality of ARMS primers possessing non-amplifiable tails in conjunction with a 'generic' array for detection amplification of variant nucleic acid
30 sequences.

Microarray (also termed hybridisation array, gene array or gene chip) technology wherein nucleic acid molecules attached to solid substrates at predefined locations in small
35 20 areas and at high density are used, in conjunction with hybridisation reactions, for identifying and discriminating target nucleic acid sequences, has advanced rapidly in the past few years. These chips or microarrays allow massive parallel data acquisition and are used, for example, in polymorphism detection, clinical mutation detection, expression monitoring, fingerprinting
40 and sequencing.

25 A variety of methods are currently available for making arrays of biological molecules. The 'dot or slot blot' approach, whereby an ordered array of DNA is vacuum blotted using a manifold, or hand blotted by capillary action, onto a porous membrane, such as
45 nylon or nitrocellulose has been around for many years (Maniatis et al., Molecular Cloning-A Laboratory Manual, First Edition, Cold Spring Harbor, 1982). Methods for preparing a
50 30 plurality of oligonucleotide sequences and for attaching these to solid supports at high density are also known in the art. For example, US Patent No. 4,562,137 describes a method of using

5 photo-activatable cross-linking groups to immobilise pre-synthesised ligands on surfaces.
Fodor et al. (Nature. 364:555-556, 1993) and US Patent No. 5,143,854 describe the 'light-
10 directed chemical synthesis' method for synthesising ligands, including oligonucleotides,
directly onto a substrate surface at the desired location. US 5,760,637 also describes methods
5 for *in situ* synthesis of oligonucleotides on solid support surfaces. In addition, such methods
for preparing microarrays can easily be automated. International Publication No. WO
15 95/35505 discloses an automated capillary dispensing device and method for applying
biological macromolecules to solid supports. International Publication No. WO 97/44134
also describes devices for delivery of small volumes of liquid (which may contain biological
20 macromolecules) in a precise manner to produce micro-sized spots on a solid surface to
generate a microarray. Similarly, International Publication No. WO 98/10858 also describes
an apparatus for the automated synthesis of molecular arrays. Techniques exist for applying
25 the oligonucleotides to the array at high density and for example, techniques exist for
applying well in excess of 10^3 distinct polynucleotides per 1 cm^2 .

15 Many of the advances in microarray technology concern increasing miniaturisation.
Aside from the ease in handling and manipulating smaller hybridisation matrices, one
30 significant advantage that smaller chips with higher density of capture probe have over larger
formats is that the sample does not have to be "stretched out". The technology is unlikely to
be widely accepted in the clinical diagnostic market however until costs have been
35 20 substantially reduced from their current levels.

Oligonucleotide DNA arrays consisting of short oligonucleotides (e.g. typically 8mers
to 20 mers) bound via their 3' termini to a solid surface such as glass or a silicon wafer have
40 been proposed as tools for mutation detection or for the resequencing of genes (e.g. Chee et.
al., Science, 1996, Vol. 274, pp 610 - 614; Drobyshev et. al., Gene, 1997, vol.188, pp 45-52).

25 The mechanism of analysing DNA sequences depends on the principles of allele specific
hybridisation. In brief, an oligonucleotide array is prepared with a set of overlapping
45 oligonucleotide probes (e.g. 20 mers) complementary to the consensus sequence of the DNA
target designed so that each sequence is offset from the previous sequence by one base pair.
As well as the consensus sequence all three variant sequences at the central nucleotide
50 30 position are also included on the array. Often the probe sequences for analysing the opposite
template strand are also included on the array. The target sequence is amplified using the

5 polymerase chain reaction (PCR) and the products are then often transcribed into RNA which
has incorporated therein a fluorescent label such as fluorescein-UTP. The labelled RNA is
10 sheared into short fragments and then hybridised to the DNA array. The most stable hybrids
form when the target sequence binds to its fully complementary sequence on the array. If
5 there is a mutation in the target sequence then it will bind to one of the variant probes more
effectively than to the consensus probe. The relative extent of binding of the target sequence
15 to the probes is measured by monitoring the intensity of fluorescence at each site on the DNA
array. If the target sequence is mutated then the fluorescence intensity will be greater at one
of the variant probe positions than at the consensus probe position.

20 10 Microarray technology also makes it possible to simultaneously study the expression
of many thousands of genes in a single experiment. Differential expression profiles from, for
example, normal versus diseased tissues or induced versus un-induced tissues can be obtained
25 by hybridising the product of expressed mRNA to complementary nucleic acid at pre-defined
locations on the array. Alternatively, a time-course of expression of thousands of genes over
15 several experiments from a single sample could be performed. Analysis of gene expression in
human tissue (i.e. biopsy tissue) can assist in the diagnosis and prognosis of disease and the
30 evaluation of risk for disease. A comparison of levels of expression of various genes from
patients with defined pathological disease conditions with normal patients enables an
expression profile, characteristic of disease, to be created. There are currently two approaches
35 20 to analyse gene expression using microarrays. In the first approach, cDNA fragments, often
generated by PCR, for each of the genes under study are attached to an array. Typically,
mRNA isolated from the test samples (i.e. induced or un-induced) is reverse transcribed into
cDNA with incorporation of a fluorescent label. The cDNA is sheared and hybridised to the
40 array. The other test sample mRNA can be reverse transcribed with incorporation of a
25 different fluorescent label to enable direct comparison of the expression level of each test gene
on the same array (see WO 95/35505). The second approach is similar to the first except that
45 an oligonucleotide microarray is used. Because of the differences in hybridisation properties
between short oligonucleotide probes, each gene must be represented by several
oligonucleotides (typically 20 or more) on the chip. In addition, a partner control
50 30 oligonucleotide identical to each oligonucleotide, except for one of the central nucleotides, is
included on the array to serve as an internal control for hybridisation sensitivity. Thus,

5
10
15
20
25
30
35
40
45
50
55

whereas cDNA arrays only require each gene to be represented by a single hybridisation partner on the array, with oligonucleotide arrays, each test gene must be represented by approximately 40 distinct oligonucleotides each at a different position on the array. The advantage of oligonucleotide arrays over cDNA arrays however, concerns the shelf-life of the sample on the array. In general, a cDNA library prepared on an array is useable for weeks whereas, pre-prepared oligonucleotide arrays can be stored for considerably longer.

The strengths of the DNA microarray concept is its ability to carry out very large numbers of hybridisation based analyses simultaneously. However, as the capture sequences attached to the support (chip) have to complement the target sequence, knowledge of the target sequence is required. Each chip has to be custom built on the basis of this known sequence. The need to develop a new custom chip for each new test renders the technology costly and complex. Other concerns involve the hybridisation conditions that must be adopted for each test. Secondary and tertiary structure formation can interfere with hybridisation of the capture and target molecules. In addition, duplex formation between different individual pairs of target sequence and capture sequence may have different stabilities (melting temperatures), because of different G-C content, for example. Current approaches to overcome some of these hybridisation problems include: applying parallel hybridisation across the array, altering the concentration of capture nucleic acid at a particular location, modifying the length of the oligonucleotide at a particular location so as to alter duplex stability, and using tuned electric fields as demonstrated by Edman et al, (Nucleic Acids Research. 25(24):4907-4914, 1997. In practice, however, as DNA duplexes between different individual sequences on the arrays and their cognate complementary target sequences have various different stabilities, custom hybridisation conditions have to be employed for each particular test. In view of the different hybridisation stabilities however, hybridisation conditions adopted are generally not optimal for each and every capture sequence on the array, but are generally a compromise. It would be advantageous to design a microarray wherein substantially the same hybridisation between each pair of target and capture molecule occurs under any chosen hybridisation conditions.

According to a first aspect of the invention there is provided a solid support having immobilised thereon a plurality of oligonucleotides at pre-defined positionally distinct sites,

characterised in that the sequence of each oligonucleotide that binds to its complementary sequence has substantially the same melting temperature (T_m).

According to one aspect of the present invention there is provided a solid support having immobilised thereon a plurality of pre-selected oligonucleotides at pre-defined positionally distinct sites, characterised in that the sequence of each oligonucleotide when bound to its complementary sequence has substantially the same melting temperature (T_m) as the other oligonucleotides on the support.

In a preferred embodiment the oligonucleotides attached to the solid support are non-complementary with genomic DNA and non complementary with each other.

With regard to the meaning of "substantially the same melting temperature (T_m)", each single-stranded oligonucleotide immobilised on the solid support has, in increasing order of preference, a T_m when bound to its complementary sequence, within 8°C, 7°C, 6°C, 5°C, 4°C, 3°C, 2°C, 1°C, and 0.5°C of the average T_m of all the oligonucleotides immobilised on the solid support. In a more preferred embodiment the oligonucleotides immobilised on the solid support will possess melting temperatures within a range of 0 to 8°C of each other. In another preferred embodiment at least 90% of the oligonucleotides on the array have melting temperatures within 4°C, preferably within 2°C of each other. In an even more preferred embodiment the oligonucleotides immobilised on the solid support will possess melting temperatures within a range of 0 to 2°C of each other. In the most preferred embodiment, 90-100% of all the oligonucleotides immobilised on the solid support will possess the same melting temperature, and the remaining oligonucleotides will preferably possess melting temperatures within a range of 0 to 2°C of this mode value.

Although it is preferred that all of the oligonucleotides on the solid support fall within the ranges or values for melting temperature as defined above, it is envisaged that a small number of oligonucleotides preferably less than 1-5%, more preferably less than 2% of the total number of oligonucleotides may fall outside these ranges or values.

The melting temperature (T_m) referred to herein, is defined as the temperature at which duplex DNA exists in a ratio of 50:50 in hybridised and dissociated form under equilibrium conditions. The principal governing factors determining T_m are sequence length and G-C content. The theoretical and experimental procedure for determining the T_m is disclosed in Molecular Cloning: A Laboratory Manual, Second Edition, J. Sambrook et al.,

5 Cold Spring Harbor, Chapter 11 section 46 and 55. In essence, for oligonucleotides shorter
than 18 nucleotides, the T_m of the hybrid is estimated by multiplying the number of A + T
10 residues in the hybrid by 2°C and the number of G + C residues by 4°C and adding the two
together. For oligonucleotides between approximately 14 and 70 nucleotides in length, the
5 following equation devised by Bolton and McCarthy, (P.N.A.S. 48:1390, 1962) for
determining T_m of long DNA molecules is also applicable:

$$15 \quad T_m = 81.5 - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\% \text{ G} + \text{C}) - (600/N).$$

Wherein N = chain length and $[\text{Na}^+]$ is the ionic strength of the hybridisation solution.

The term "nucleotide" as used herein can refer to nucleotides present in either DNA or
20 RNA and thus includes nucleotides which incorporate adenine, cytosine, guanine, thymine
and uracil as base, the sugar moiety being deoxyribose or ribose. It will be appreciated
however that other modified bases capable of base pairing with one of the conventional bases,
25 adenine, cytosine, guanine, thymine and uracil, may be used in the oligonucleotides, probes or
primers employed in the present invention. Such modified bases include for example
15 8-azaguanine and hypoxanthine.

The term "oligonucleotide" as used herein is defined as a molecule comprised of two
30 or more nucleotides (i.e. deoxyribonucleotides or ribonucleotides), preferably more than five.
Its exact size will depend on many factors, such as the reaction temperature, salt
concentration, the presence of denaturants such as formamide, and the degree of
35 20 complementarity with the sequence to which the oligonucleotide is intended to hybridise.

In operation, under any hybridisation conditions adopted, all of the oligonucleotides
on the solid support (herein referred to as "capture oligonucleotides") that are to be used for
capture of a target sequence, exhibit approximately the same hybridisation stability with their
40 cognate complementary sequence as the other pairs of oligonucleotide and complementary
25 target sequence. This ensures that approximately equivalent amounts of target DNA are
bound to the complementary oligonucleotide on the array at any particular time, facilitating
45 quantitative analysis. As the T_m of all the duplexed oligonucleotides will be substantially the
same however, the optimum temperature for hybridisation can be adopted. With
oligonucleotide hybridisation, the optimum hybridisation temperature is generally carried out
50 30 under conditions that are 5-10°C below the T_m , with the hybridisation and subsequent washes
carried out under stringent conditions. Ideally, the hybridisation temperature is controlled

precisely, preferably to $\pm 2^{\circ}\text{C}$, more preferably to $\pm 0.5^{\circ}\text{C}$ or better, particularly when the hybridisable length of the capture oligonucleotides are small and there is a need to discriminate between two sequences that may only differ by a single nucleotide at one or other of the termini of the hybridisable sequence. It will be apparent that the capture oligonucleotides need not all be of the same length. Depending on their relative G-C content, two oligonucleotides of different lengths may nevertheless, have the same T_m . Capture oligonucleotides of substantially the same length and G-C content are preferred however.

According to a further aspect of the invention there is provided a solid support having immobilised thereon a plurality of pre-selected oligonucleotides at pre-defined sites, characterised in that the capture portion of all of the oligonucleotides are of substantially the same length and they all have substantially the same G-C content.

With regard to the meaning of "substantially the same length", in increasing order of preference, the length of each capture portion of the oligonucleotide immobilised on the solid support will be within or equal to 16, 12, 10, 8, 6, 5, 4, 3, 2, and 1 nucleotide(s) of the average length of all the capture portions of the oligonucleotides immobilised on the solid support. In a preferred embodiment the oligonucleotide capture portions will each be of a length that is within 0-8 nucleotides of each other.

With regard to the meaning of "substantially the same G-C content", in increasing order of preference, each of the oligonucleotides immobilised on the solid support will have a G-C content within or equal to 25%, 20%, 15%, 10%, 10%, 5% and 2% of the average G-C content of all the immobilised oligonucleotides. In a preferred embodiment, 95-100% of all the oligonucleotides immobilised on the support will have a percentage G-C content within 10% of the median value and the remainder will preferably be within 25% of the median value. More preferably the percentage G-C content of the oligonucleotides immobilised on the solid support will be within 8% of each other.

In a preferred embodiment the capture portion of all of the oligonucleotides are of the same length and have the same G-C content.

Although it is preferred that all of the oligonucleotides on the solid support fall within the ranges for length and G-C content as defined above, it is envisaged that a small number of oligonucleotides preferably less than 1-5%, more preferably less than 2% of the total number of oligonucleotides may fall outside these ranges. The presence of oligonucleotides on the

5 solid support that possess capture sequences that fall outside the preferred sequence
composition (i.e. length and G-C content) need not diminish the utility of the generic array
10 particularly if these capture sequences are excluded from being used as capture molecules
when the array is in use.

5 In a further preferred embodiment there are at least 50 different oligonucleotides
immobilised on the solid support, and in increasing order of preference, there are at least 100,
15 500, 1000, 5000, 10000 or more different oligonucleotides immobilised on the solid support.
In the most preferred embodiment, there are between 50 and 500 different oligonucleotides
immobilised on the solid support.

20 In a further embodiment, the oligonucleotides are immobilised on the solid support at
a density in the range of, in increasing order of preference, 1 to 1000 per cm², 200 to 1000 per
cm², 200 to 500 per cm², 1 to 200 per cm², 1 to 50 per cm², and 1 to 10 per cm². Most
25 preferred is about 100 per cm². In a particular embodiment each distinct capture
oligonucleotide is immobilised to the base of a well of a conventional microtitre plate.

15 Although it is preferred that the oligonucleotides at each pre-determined location on
the solid support are unique, this is not essential. Duplicate, triplicate etc., representation of
30 one, more or all capture oligonucleotides on the solid support (array) may be desired in order
to detect replicate values.

The capture oligonucleotides attached to the solid support generally have a
35 20 hybridisable sequence between 5 and 100 nucleotides in length. The preferred length of
hybridisable sequence is in the range of 10 - 50, more preferred is 20 - 35, still more preferred
is 12-30. The hybridisable sequence is that portion of the capture oligonucleotide (capture
40 portion) that is designed and available for hybrid formation with its complementary sequence.
As used herein in reference to hybridisable sequence and capture portion are used
25 interchangeably. Non-hybridisable sequence of the capture oligonucleotide might represent
flanking or tether sequences. Tether sequences not only serve to anchor the oligonucleotide to
45 the solid support but also serve to distance the hybridisable portion of the capture
oligonucleotide from the solid support to alleviate steric interference.

The primary structure of each unique capture oligonucleotide on the array can either
50 30 be designed manually, or can be designed using a computer program to generate random
nucleotide sequences. A suitable macro for randomly designing oligonucleotides is disclosed

5 in example 2 herein. It is preferable that none of the capture oligonucleotides on the array
(solid support) are capable of hybridising, under stringent hybridisation conditions adopted, to
10 any of the sample target sequences. In this respect, it is preferred that none of the capture
oligonucleotides are capable of hybridising with any part of the genome of the test organism
5 under study, be this human, simian, bacterial, viral or the like. In a more preferred
embodiment all of the capture oligonucleotides on the array are artificial and lack
15 complementarity to any known sequence from whatever origin. It is also preferred that none
of the capture oligonucleotides cross-hybridise to any test sample nucleic acid. However, if
one or more of the capture oligonucleotides on the array do bind to a test sample nucleic acid,
20 10 this is not detrimental provided that it is known in advance so that any false positive result can
be discounted.

The capture oligonucleotide molecules may be individually synthesised on a standard
25 oligonucleotide synthesiser. These oligonucleotide (oligos) may then be attached to the
substrate matrix by any of a variety of techniques known in the art such as by using
15 photochemical reagents, such as disclosed in US Patent No. 4,542,102 and 4,713,326. US
Patent No. 4,562,157 also describes a method of using photo-activatable cross-linking groups
30 to immobilise pre-synthesised ligands on surfaces. Alternatively, the oligonucleotides can be
synthesised directly onto the solid surface using photolithography techniques, such as
disclosed in US Patent No. 5,143,854, or other methods such as disclosed in US Patent No.
35 20 5,700,637, or International Publication No's: WO 95/35505, WO 97/44134 or WO 98/10858.
Schena et al. (TIBTECH 16(7):301-306, 1998) reviews the recent advances in microarray
technology including the various means of constructing these arrays. Problems facing current
40 photolithographic techniques for nucleotide synthesis involve the low yield of synthesis
at each synthesis step, and also the efficiency of nucleotide addition at each synthesis step
25 which can range from about 80% to 97%, with purines generally having a lower efficiency
than pyrimidines (Thomas & Burke. Exp. Opin. Ther. Patents 8(5):503-508, 1998). When
45 constructing an array with relatively few capture oligonucleotides, say 500 or less, or with
long oligonucleotides say 30-mers or more it may be preferable to synthesise the oligos
separately and affix them to the solid support later rather than in situ synthesis.

50 30 According to a further aspect of the present invention there is provided a method for
the preparation of a generic oligonucleotide microarray of the invention, comprising

5 synthesising a plurality of different oligonucleotides and then affixing them to a solid support
at a pre-defined location, wherein each oligonucleotide possesses substantially the same T_m as
10 the other oligonucleotides when annealed to its complementary sequence. In a preferred
embodiment the oligonucleotides are synthesised on a standard oligonucleotide synthesiser
5 such as an Applied Biosystems model 340A synthesiser.

15 According to a further aspect of the invention there is provided a method for the
preparation of a generic oligonucleotide microarray, comprising directly synthesising onto a
solid support at pre-defined positions a plurality of different oligonucleotides, each
oligonucleotide possessing substantially the same T_m as the other oligonucleotides when
20 annealed to its complementary sequence. In a preferred embodiment said synthesis is by the
photolithography technique as described in US Patent No. 5,143,854.

In order to avoid or alleviate steric factors during the capture hybridisation reaction, it
25 may be desirable to use a tether/linker molecule to tether the capture oligonucleotides to the
solid support. Shchepinov et al. (N.A.R. 25:1155-1161, 1997) disclose the use of various
15 amino group-containing phosphoramidite moieties to distance the capture oligonucleotide
from the solid support and thus alleviate steric interference. They found that with a linker of
30 at least 40 atoms in length they obtained up to 150-fold increased hybridisation yields. Based
on the teaching in Shchepinov et al., the person skilled in the art would be able to design and
synthesise suitable tether/linker molecules to reduce steric interference of the support on
35 20 hybridisation behaviour of the immobilised capture oligonucleotides of the invention.

Thus, in a preferred embodiment the oligonucleotides are attached to the solid support
via a tether molecule, such as disclosed in Shchepinov et al. (N.A.R. 25:1155-1161, 1997).

40 The novel array with its population of unique capture oligonucleotides is generally
used in conjunction with targeting polynucleotide molecules (herein referred to as "targeting
25 polynucleotides").

The targeting polynucleotides are comprised of two adjacent oligonucleotide
45 sequences, optionally separated by a spacer molecule. The first sequence of the targeting
polynucleotide is complementary to one of the capture oligonucleotide sequences on the array.
The second sequence is complementary to or substantially complementary to the target
50 30 sequence to be detected and can therefore act as a detection probe or as an amplification
primer. Although the targeting sequence (the second sequence) need not reflect (be precisely

complementary to) the exact sequence of the target, the more closely it does reflect the exact sequence the better the binding during the annealing process.

The term "polynucleotide" as used herein is used to define a molecule composed of ten or more deoxyribonucleotides or ribonucleotides, preferably more than 25. A polynucleotide molecule may be made up of two or more oligonucleotide molecules.

The term "complementary to" is used herein in relation to nucleotides to mean a nucleotide which will base pair with another specific nucleotide. Thus adenosine triphosphate is complementary to uridine triphosphate or thymidine triphosphate and guanosine triphosphate is complementary to cytidine triphosphate. It is appreciated that whilst thymidine triphosphate and guanosine triphosphate may base pair under certain circumstances they are not regarded as complementary for the purposes of this specification. It will also be appreciated that whilst cytosine triphosphate and adenosine triphosphate may base pair under certain circumstances they are not regarded as complementary for the purposes of this specification. The same applies to cytosine triphosphate and uracil triphosphate.

"Precise complementarity" or "perfectly matched" as used herein, is in reference to the duplex that the poly- or oligonucleotide strands make with one another to form a double stranded structure such that every nucleotide in each strand undergoes Watson-Crick base pairing with a nucleotide on the other strand. The term also encompasses the pairing of nucleoside analogues, such as deoxinosine, nucleotides with 2-aminopurine bases, and the like, that may be employed. Conversely, a mismatch in a duplex fails to undergo Watson-Crick bonding.

"Substantially complementary" as used herein, refers to poly- or oligonucleotide molecules (or strands) that, under suitable hybridisation conditions (i.e. with reduced stringency), have sufficient complementarity to specifically anneal together, i.e. to the exclusion of all other strands, to form a double stranded structure, but wherein one or other strand has, relative to its partner, a limited number of non-complementary (mismatched) nucleotides that are incapable of undergoing Watson-Crick base pairing with the corresponding nucleotide on the other (partner) strand. In a preferred embodiment the number of mismatch nucleotides does not exceed 20%, more preferably 15%, and still more preferably 10% of the total number of nucleotides in the poly- or oligonucleotide.

5

The targeting polynucleotide molecules may be individually synthesised on a standard oligonucleotide synthesiser.

10

When the targeting polynucleotides are for use as amplification primers, the 5' portion is preferably blocked from acting as template for the polymerase enzyme. This blocking can be effected by linking the 3' portion and the 5' portion of the polynucleotide in the opposite sense to one another, the 3' end being generally in the 5' → 3' sense and the 5' end of the polynucleotide being in the 3' → 5' sense, with linkage via their 5' termini. The presence of the nucleotide sequence of the 5' portion in the opposite orientation prevents the polymerase enzyme from making a fully double stranded amplification product. The 5' portion of the polynucleotide thus becomes a single stranded tail on the amplification product. This single stranded tail (the 5' end portion) can then be utilised for capture of the amplification product onto the complementary capture oligonucleotide attached to a solid support. The more preferred means of blocking the polymerisation agent however, is to incorporate a blocking moiety (as the spacer moiety) between the 5' portion and 3' portion of the targeting polynucleotide.

25

30

The term " blocking moiety" as used herein means any moiety which when linked, for example covalently linked, between the 3' portion and 5' portion of the polynucleotide is effective to inhibit and preferably prevent, more preferably completely prevent amplification (which term includes any detectable copying) beyond the polymerisation blocking moiety, thus leaving the amplification product with a single stranded tail which is the 5' portion of the polynucleotide. A wide range of blocking moieties may be envisaged for this purpose. For example the polymerisation blocking moiety may comprise a bead, for example a polystyrene, glass or polyacrylamide bead or the polymerisation blocking moiety may comprise a transition metal such as for example iron, chromium, cobalt or nickel (for example in the form of a transition metal complex with the oligonucleotide tail and the target binding nucleotide moiety) or an element capable of substituting phosphorus such as for example arsenic, antimony or bismuth linked between the oligonucleotide tail and the target binding nucleotide moiety. The blocking moiety might similarly involve substitution of the usual phosphate linking groups, for example where oxygen is replaced, leading to *inter alia* phosphorodithioates, phosphorothioates, methylphosphonates, phosphoramidates such as phosphormorpholides, or other residues known *per se*. Alternative blocking moieties

35

40

45

50

55

5 include any 3'-deoxynucleotide not recognised by restriction endonucleases and *seco*
nucleotides which have no 2'-3' bond in the sugar ring and are also not recognised by
10 restriction endonucleases. Newton et al. (Nucleic Acids Research. 21(5):1155-1162, 1993)
and EP-B-416817, describe tailed primers with blocking moieties, interposed between the tail
5 and the target binding portion of the primer, that can be incorporated into the polynucleotides
of this invention.

15 In a preferred aspect the spacer comprises a non-amplifiable blocking moiety such as
hexethylene glycol (HEG) monomer, alone or combined with further nucleotides, more
preferably alone. Alternatively the spacer could comprise material such as 2'-O-alkyl RNA
20 which will not permit replication of a complementary strand by DNA polymerase enzymes
that lack a reverse transcriptase function.

To avoid false positive detection using the microarray and the targeting
25 polynucleotides of the invention, it is desirable that none of the targeting polynucleotides are
capable of hybridising to each other. Naturally, it is also desirable that none of the tails (the
15 5' portions of the targeting polynucleotides) nor spacer moieties are capable of binding to any
nucleic acid in the nucleic acid sample. If the capture hybridisation is to be effected in the
30 presence of all the test sample nucleic acid, i.e. without separation of targeting polynucleotide
bound nucleic acid from unbound nucleic acid, it is also desirable that none of the capture
oligonucleotides on the solid support are capable of binding to any target nucleic acid in the
35 20 original test sample.

According to a further aspect of the invention there is provided a plurality of
polynucleotides, each polynucleotide comprising a unique 3' portion substantially
40 complementary to a unique target nucleic acid sequence which may be present in a sample, a
5' portion complementary to one of a group of pre-selected oligonucleotides that each possess
25 substantially the same melting temperature (T_m) and are attached at pre-defined positions to a
solid support, and optionally a spacer moiety interposed between said 3' portion and said 5'
5 portion.

In a preferred embodiment, each of the unique 3' portions is precisely complementary
with its cognate target sequence. It is to be expected however, that not all the target
50 30 sequences, complementary to each and every unique 3' portion, will be present in a test
sample.

5

In another preferred embodiment, each of the unique 5' portions from within the population of polynucleotides has substantially the same G-C content and substantially the same length as each of the other 5' end portions.

10

In a more preferred embodiment, each of the unique 5' portions from within the population of polynucleotides has the same G-C content and length as each of the other 5' end portions.

15

The 3' portion of the targeting polynucleotide represents the target binding sequence. This sequence can be of any length although it will preferably be between 8 and 60 nucleotides in length, more preferably between 12 and 35 nucleotides in length. The target binding portion of the targeting polynucleotide sequence need not possess precise complementarity to the target sequence however, it must have sufficient complementarity (be substantially complementary) to bind specifically to the target sequence, that is to say under appropriate hybridisation stringency conditions the target binding region of the primer will hybridise to the target region (if present in the sample) to the exclusion of other regions.

20

25

There are applications, such as with the ARMS technique, where nucleotide mismatches are incorporated into the target binding primer in order to assist in destabilising primer binding to incorrect target sequences. The presence of certain mismatches need not however, prevent primer binding to the desired target template sequence. In general however, and particularly when relying on allele specific hybridisation, it is preferred that the target binding portion of the targeting polynucleotides has precise complementarity to its target sequence.

30

35

The expression "target nucleotide sequence" or "target nucleic acid" or "target sequence" as used herein means a nucleotide or nucleic acid sequence comprising the sequence to be detected by probe or amplified by primer. Thus for example, if the present invention is applied to the diagnosis of β -thalassaemias a sample may contain as many as 60, for example 50, separate potential variant sequences. Each variant sequence is a potential target sequence for probe hybridisation or primer amplification according to the invention disclosed herein.

40

45

Amplification of the target sequence can be effected by primer extension off one primer, however, in a preferred embodiment, each targeting oligonucleotide primer is accompanied by a companion primer which facilitates amplification of the target sequence

50

55

interposed between the two primers according to amplification procedures such as polymerase chain reaction (PCR) or ligase chain reaction (LCR), well known in the art.

When the targeting polynucleotides are for use as allele-specific probes for detecting the presence of a target sequence, the spacer moiety interposed between the two hybridisable elements can serve to prevent steric interference of the two hybrid elements, these two elements being the hybrid duplex molecule consisting of the oligonucleotide targeting portion (the 3' portion) and its complementary sequence from the test sample, and the hybrid duplex consisting of the capture oligonucleotide on the array and the complementary sequence on the targeting oligonucleotide (the 5' portion). The spacer moiety might consist of straight chain or branched alkyl groups, polyglycol residues of any desired number of repeating unit, or modified nucleotides such as 2'-deoxyribose or 1'napthalene-2'-deoxyribose may be interposed between the first and second portions of the targeting oligonucleotides so as to provide spatial distance between the capture hybrid and the target hybrid.

The capture hybrid refers to the duplex molecule formed by annealing the capture oligonucleotide to the 5' portion (the single stranded "tail") of the targeting polynucleotide. This targeting polynucleotide may or may not already have bound its target sequence. The target hybrid refers to the duplex molecule formed by annealing of the target binding portion (the 3' end) of the targeting polynucleotide to its target sequence. Although the target and capture hybrids have been referred to as duplex molecules, it will be apparent that each complex may not be entirely double stranded.

An advantage of the invention is that the target product, either probe-target hybrid or amplified product, has a single-stranded portion which can be hybridised without denaturation to the solid support containing the immobilised pre-selected capture oligonucleotide sequences. Current array technology requires the target nucleic acids to be denatured or rendered single-stranded some other way, prior to capture on the array.

The microarray and targeting polynucleotides of the invention are useful in any setting where it is desirable to identify the presence of one or more specific nucleic acid sequences from a population of sequences. Examples of uses are in *de novo* or re-sequencing methods, gene expression studies, fingerprinting, diagnostic identification, genotyping of organisms and environmental monitoring.

5 Any population of nucleic acids represents a suitable test sample. Sources of test
sample nucleic acid include human cells such as circulating blood, buccal epithelial cells,
10 cultured cells and tumour cells. Other mammalian tissues and cultured cells are also suitable
sources of template nucleic acids. In addition, viruses, bacteriophage, bacteria, fungi and
5 other micro-organisms can be the source of nucleic acid for analysis. The DNA may be
genomic or it may be cloned in plasmids, bacteriophage, bacterial artificial chromosomes
15 (BACs), yeast artificial chromosomes (YACs) or other vectors. RNA may be isolated directly
from the relevant cells or it may be produced by *in vitro* priming from a suitable RNA
promoter or by *in vitro* transcription.

20 10 The present invention may be used for the detection of variation in genomic DNA
whether human, animal or other. It finds particular use in the analysis of inherited or acquired
diseases or disorders. A particular use is in the detection of inherited disease. It will be
25 appreciated that the target nucleic acid is directly or indirectly linked to the sequence or region
of interest for analysis.

15 According to a further aspect of the invention there is provided a method for
identifying the presence or absence of one or more test nucleic acid sequences in a sample,
30 comprising the following steps:

- 35 i) contacting a nucleic acid containing sample with a plurality of single stranded
targeting polynucleotide molecules under suitable hybridisation conditions to ensure hybrid
20 formation between the targeting nucleotide portion of the targeting polynucleotide molecule
35 and its complementary target nucleic acid sequence in the sample, each of said targeting
polynucleotide molecules possessing, in addition to the targeting nucleotide portion, a unique
single-stranded oligonucleotide tail sequence complementary to a unique capture
40 oligonucleotide attached to a solid support;
- 25 ii) contacting the population of hybrid molecules produced in step (i) to a solid support
having attached thereon at pre-defined locations unique capture oligonucleotides, each capture
45 oligonucleotide being complementary to one or other of the oligonucleotide tail sequences on
the targeting molecules, under suitable conditions to ensure capture of each of the hybrid
products to the solid support; and
- 50 iii) determining the presence or absence of the captured product at each of the pre-
defined locations on the solid support by measurement of a detectable label suitable to

5 identify the captured products; characterised in that substantially all of the oligonucleotide
tails of the targeting polynucleotide molecules and the complementary sequences on the
10 capture oligonucleotides possess substantially the same T_m .

According to a further aspect of the invention there is provided a method for
5 identifying the presence or absence of one or more test nucleic acid sequences in a sample,
comprising:

- 15 i) contacting a nucleic acid containing sample with a plurality of single stranded targeting
polynucleotide molecules under suitable hybridisation conditions to ensure hybrid formation
between the targeting nucleotide portion of the targeting polynucleotide molecule and its
20 complementary target nucleic acid sequence in the sample, each of said targeting
polynucleotide molecules possessing, in addition to the targeting nucleotide portion, a unique
single-stranded oligonucleotide tail sequence complementary to a unique capture
oligonucleotide sequence attached to a solid support, characterised in that substantially all of
25 the oligonucleotides the capture sequence of each oligonucleotide and its complementary
sequences on the tail possess substantially the same T_m ;
- 30 ii) contacting the population of hybrid molecules produced in step (i) to a solid support having
attached thereon at pre-defined locations unique capture oligonucleotides, each capture
oligonucleotide being complementary to one or other of the oligonucleotide tail sequences on
the targeting molecules, under suitable conditions to ensure capture of each of the hybrid
35 products to the solid support; and
- 40 iii) determining the presence or absence of the captured product at each of the pre-defined
locations on the solid support by measurement of a detectable label suitable to identify the
captured products.

In a preferred embodiment, the hybrid molecules produced in step (i) are separated
25 from the unhybridised targeting molecules prior to step (ii). This may be conveniently done
by, for example, ethanol precipitation, column chromatography or gel filtration.

45 In operation, the targeting polynucleotide binds to the target nucleic acid in the sample
("the wet reaction"). If the targeting polynucleotide is serving as a probe, for example as in an
allele specific hybridisation, the hybrid molecule is available for capture via the unhybridised
50 single stranded tail portion of the targeting polynucleotide which is complementary to a
capture oligonucleotide attached at pre-defined position on the solid support.

5

In a preferred embodiment the targeting polynucleotide possesses a detectable label.

10

If the targeting polynucleotide is serving as an amplification primer, an amplification reaction must be carried out on the polynucleotide-bound target nucleic acid sample. Multiple rounds of primer extension from the primer can be effected in order to amplify the target

15

nucleic acid such as up to 5, up to 10, up to 15, up to 20, up to 30, up to 40, up to 50 or more times. Conveniently, the targeting polynucleotide is serving as an amplification primer in an amplification system such as the polymerase chain reaction (PCR). In which case the target binding region (3' end) and the tail region (5' end) are advantageously arranged such that the tail region is non-amplifiable in the PCR amplification reaction but remains single stranded,

20

thus ensuring that the amplified product has at least one single stranded tail complementary to a capture oligonucleotide on the solid. This facet of primer design is described in European Patent No. 0 416 817 and corresponding US Patent No. 5525494. In order to effect amplification using PCR-based or LCR-based procedures, a second primer is required. This second oligonucleotide primer may also have a non-amplifiable single stranded tail, possibly identical to the capture portion of the targeting polynucleotide so as to facilitate capture on the solid support. This second primer might also be suitably labelled to facilitate detection of the captured amplification product on the solid support. Alternatively, a suitable label (such as a labelled nucleoside tri-phosphate) might be incorporated into the amplified product during the amplification process.

25

30

35

Any convenient template dependent polymerase may be used, this is preferably a thermostable polymerase enzyme such as Taq™, more preferably Taq Gold™.

40

Similarly any convenient nucleoside triphosphates for conventional base pairing may be used. If required these may be modified for fluorescence. As these may affect polymerisation rates, for best results, the fluorescently labelled dNTPs are admixed with an excess of wild-type dNTPs, for example in an admixture of between about 1:3 and 1:20.

Further details of convenient polymerases, nucleoside triphosphates, other PCR reagents, primer design, instruments and consumables are given in: "PCR" by C.R. Newton and A. Graham (The Introduction to Biotechniques series, Second Edition 1997, ISBN 1 85996 011 1, Bios Scientific Publishers Limited, Oxford). Further guidance may be found in "Laboratory protocols for mutation detection" edited by Ulf Landegren, published by the Oxford University Press, Oxford, 1996, ISBN 0 19 857795 8.

45

50

55

5

10

15

20

25

30

35

40

45

55

In a preferred embodiment, the targeting polynucleotide molecules are amplification primers, such as those disclosed in EP-B-416817. In a further preferred embodiment, the targeting amplification primer molecules are used in conjunction with another amplification primer to amplify the target region of interest. In a more preferred embodiment, the amplification primers are amplification refractory mutation system (ARMS) primers, as described in EP-B-0332435 and corresponding US Patent No. 5595890, and additionally described in Newton et al. (Nucleic Acids Research. 17(7):2503-2516, 1989). ARMS is a technique suitable for detecting the presence or absence of variant nucleotides at a particular loci. It is particularly useful therefore, in diagnostic detection of mutated nucleic acid indicative of tumour phenotype, or in the detection of single nucleotide polymorphisms (SNPs). ARMS is a particularly useful technique where the target sequence is present in low copy number or there is a need to discriminate between two or more alleles, as for example in mutation detection. ARMS mutation detection enables the sensitive detection of specific alleles in the presence of an excess of alternate alleles. In this way somatic mutations can be detected in a background of wild type DNA. ARMS can readily be used to detect 1% mutant sequence in a 99% wild-type background. ARMS uses primers that allow amplification in an allele specific manner. Allele specificity is provided by the complementarity of the 3'-terminal base of a primer with its' respective allele. Amplification is inhibited when the 3'-terminal base of the primer is mismatched. This specificity is maintained when Taq DNA polymerase or other suitable enzyme lacking 3' to 5' proof-reading activity (such as Klenow) is used. An ARMS test is specific when the yield of product from the target allele exceeds the threshold of detection of the system in use and the yield of product from the nontarget allele is not detectable. As disclosed in EP-B-0332435 the ARMS primers will preferably possess destabilising mismatches incorporated close to the 3'-terminal nucleotide that discriminates between the different alleles, to enhance specific binding and template amplification from the desired allele target sequence. The nearer to the 3' terminus of the primer that a destabilising mismatch is incorporated, the greater the effect on destabilisation (See also Newton et al. Nucleic Acids Research. 17:2503-2516, 1989).

In another preferred embodiment, the second amplification primer for amplifying any particular target sequence possess an oligonucleotide tail identical to that of the first targeting primer. In a further preferred embodiment, the second amplification primer possesses a

5 detectable label, such as a fluorophor or radioisotope to enable the eventual detection of the
amplified product on the microarray. In a further preferred embodiment either or both primer
10 molecules possess a detectable label. Suitable labelling molecules are well known in the art.
Alternatively, a suitable label can be incorporated into the amplified product during its
5 synthesis. A suitable amplification reaction can then be performed so as to generate an
amplification product.

15 It will be apparent to the person skilled in the art that there are a large number of
analytical procedures which may be used to detect the presence or absence of variant
nucleotides at one or more polymorphic positions. Most of these rely on probe or primer
20 hybridisations and thus, with addition of a suitable tail portion to enable capture on an array
could be adopted for use with the microarray and method of the present invention. In general,
the detection of allelic variation requires a mutation discrimination technique, optionally an
25 amplification reaction and a signal generation system. Table 1 lists a number of mutation
detection techniques, some based on the polymerase chain reaction (PCR). These may be
15 used in combination with a number of signal generation systems, a selection of which is listed
in Table 2. Many current methods for the detection of allelic variation are reviewed by Nollau
30 *et al.*, Clin. Chem. 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory
Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and
"PCR", 2nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997. PCR is
35 20 described in United States patents nos. 4,683,195 and 4,683,202.

Abbreviations:

40 ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMST™	Amplification refractory mutation system
b-DNA	Branched DNA
45 CMC	Chemical mismatch cleavage
COPS	Competitive oligonucleotide priming system
FRET	Fluorescence resonance energy transfer
50 LCR	Ligase chain reaction

MASDA	Multiple allele specific diagnostic assay
NASBA	Nucleic acid sequence based amplification
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
SDA	Strand displacement amplification
SSR	Self sustained replication

Table 1 - Mutation Detection Techniques

MASDA; Taqman™ - US-5210015 & US-5487972; Molecular Beacons - Tyagi *et al.* Nature Biotechnology. 14:303, (1996) and WO 95/13399; ARMS™; ALEX™ - European Patent No. EP 332435 B1; COPS - Gibbs *et al.* Nucleic Acids Research. 17:2347, 1989; APEX; OLA; SSR; NASBA; LCR; SDA; b-DNA; and minisequencing- Pastinen *et al.* Genome Research. 7:606-614, 1997.

Table 2 - Signal Generation or Detection Systems

Fluorescence: Fluorescence intensity, FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom Patent No. 2228998.

Other: Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry.

When the targeting polynucleotides are operating as allele-specific probes, the target nucleic acids is preferably labelled in order to be able to discriminate targeting polynucleotides bound to the capture oligonucleotides on the array that have target nucleic acid attached from those that do not. According to one way to do this, the nucleic acid are degraded to form fragments, degradation is preferably random using for example sonication or shearing, to generate average lengths of target nucleic acid around the lengths of the complementary sequences on the targeting oligonucleotides. These fragments can then be labelled. Any number of conventional detectable markers such as radioisotopes, fluorescent labels, chemiluminescent compounds, labelled binding proteins, magnetic labels, spectroscopic markers and linked enzymes might be used. One particular example well known in the art is end-labelling with ³²P. Fluorescent labels are preferred because they are

5

10

15

20

25

30

35

40

45

50

55

less hazardous than radiolabels, they provide a strong signal with low background and various different fluorophors capable of absorbing light at different wavelengths and/or giving off different colour signals exist to enable comparative analysis in the same analysis. For example, fluorescein gives off a green colour, rhodamine gives off a red colour and both together give off a yellow colour. If the target bound targeting oligonucleotides are not separated from unbound targeting oligonucleotides (following step (i) of the method disclosed herein), and the target nucleic acid is not specifically labelled, other means of discriminating between those captured targeting oligonucleotides that have bound their cognate target sequence from the test sample from those that have not bound their test sample will be required. Suitable means for doing this include the use of intercalating agents (i.e. dyes such as ethidium bromide) that become incorporated into duplex nucleic acid or the use of labelled binding proteins or antibodies or other reagents that recognise helix formation (such as the target nucleic acid/targeting oligonucleotide hybrid), see for example US Patent No. 4,582,789, or the use of a ligand binding to the minor groove such as Hoechst 33258 fluorescent dye or the use of fluorescently labelled ligands which recognise the minor groove of DNA in a sequence specific manner, see for example, "Recognition of the Four Watson-Crick Base Pairs in the DNA Minor Groove by Synthetic Ligands." S. White, J. W. Szewczyk, J. M. Turner, E. E. Baird and P. B. Dervan, Nature, 391, 468 (1998). Convenient intercalators will be apparent to the person skilled in the art (cf Higuchi et al. BioTechnology. 10:413-417, 1992). In a preferred embodiment of the invention, capture of the hybrid detection product by the oligonucleotide on the solid support is detected using one or more minor groove binding probes.

It will be apparent to the person skilled in the art that there are other conventional detection means that can be employed in order to detect target bound polynucleotides captured on the solid support. The essential feature is that hybridisation of the captured target nucleic acid bound targeting polynucleotide onto the capture oligonucleotide on the microarray causes a detectable change in a signalling system. Any convenient signalling system may be used, by way of non-limiting example we refer to the measurement of the change in fluorescence polarisation of a fluorescently labelled species (European Patent No. 0 382 433), DNA binding proteins, intercalators, or the incorporation of detectable (modified) dNTPs into the primer extension products or the target nucleic acids.

Further systems include two-component systems where a signal is created or abolished when the two components are brought into close proximity with one another. Alternatively, a signal is created or abolished when the two components are separated following binding of the target binding region.

Both elements of the two component system may be provided on the same or different molecules. By way of example the elements are placed on different molecules, target specific binding displaces one of the molecules into solution leading to a detectable signal. One of the components may be attached to the capture oligonucleotide, or the solid support itself. For example, the array could consist of fluorescein labelled oligonucleotides of, for example 20 residues in length. Prior to addition of the sample, a set of short quencher oligonucleotides (say 10 residues in length) complementary to the array and labelled with DABCYL (or methyl red) could be added to the array. The short complementary DABCYL oligonucleotides bind to the corresponding 'address' on the array and the fluorescence of the fluorescein labels is quenched. The sample is then purified so that unextended primers or unbound probes are separated from extended or bound products. The bound or amplified products are then added to the microarray and the tail portions which are fully complementary to the oligonucleotides on the microarray bind to the microarray with displacement of the quencher oligonucleotides. This results in the microarray oligonucleotides fluorescing as a result of the binding of the appropriate product (see Figure 1). In this format a fluorescent signal is produced by separating two species bound to the array surface. One advantage of this format is that it permits quality control of the array. When the fluorescent array is manufactured it can be scanned in a fluorescent scanner and any defects such as a probe oligonucleotide which has failed to attach to the surface will be detected as a non or weakly fluorescent spot on the array. Efficient quenching when the quencher oligonucleotides are added can also be monitored before the test products are added.

Convenient two-component systems may be based on the use of energy transfer, for example between a fluorophore and a quencher. In a particular aspect of the invention the detection system comprises a fluorophore/quencher pair. Convenient and preferred attachment points for energy transfer partners may be determined by routine experimentation. A number of convenient fluorophore/quencher pairs are detailed in the literature (for example Glazer et al, Current Opinion in Biotechnology. 8:94-102, 1997,) and in catalogues such as

5 those from Molecular Probes, Glen and Applied Biosystems (ABI). Any fluorescent molecule
is suitable for signalling provided it may be detected on the instrumentation available. Most
10 preferred are those compatible with the 488 nm line of the Argon ion laser (Fluorescein and
Rhodamine derivatives). The quencher must be able to quench the dye in question and this
5 may be via a Fluorescence Resonance Energy Transfer (FRET) mechanism involving a
second, receptor fluorophore, or more preferably via a collisional mechanism involving a non-
15 fluorogenic quencher such as DABCYL, which is a "Universal" quencher of fluorescence or
methyl red. Furthermore it is preferred that the selected fluorophores and quenchers are
incorporated, most conveniently via phosphoramidite chemistry, into the capture
20 oligonucleotides and/or targeting polynucleotides and/or second primer required for example,
when undertaking PCR-based amplification. FAM, a fluorescein dye with an excitation
optimum at ~490nm, is a convenient donor.

25 In another embodiment of the invention the oligonucleotides on the support ("array")
are detectably labelled.

15 A further embodiment consists of a fluorescently labelled DNA array where the array
oligonucleotides are labelled with a fluorophore which either does not fluoresce at the
30 irradiation frequency or is only weakly fluorescent at this frequency. The ARMS primers are
labelled with a fluorophore which is substantially fluorescent at the irradiation frequency and
which forms an energy transfer pair with the fluorophore label on the DNA array. When the
35 20 purified ARMS products are bound to the array and subjected to irradiation there is energy
transfer between the fluorophore on the ARMS product and that on the array. The array
fluorophore at the specific binding sites increase substantially in its fluorescent brightness and
this may be detected by scanning the array. This is an example of increasing the fluorescent
40 signal on the array by bringing two species close together by hybridisation.

25 The oligonucleotide microarrays and targeting polynucleotides of the invention can be
used for large scale hybridisation assays in numerous applications, including genetic and
45 physical mapping of genomes, gene expression studies, sequencing, fingerprinting and
genotype mapping, genetic diagnosis and environmental monitoring. The microarray,
targeting polynucleotides and method of the invention are particularly suitable for differential
50 30 gene expression studies. When utilising the generic array and method of the present invention
for assessing expression levels of certain genes, RNA can be isolated from a cell or cell

5 population and labelled, for example by attaching a fluorescent molecule to isolated RNA or
by end labelling using T4 polynucleotide kinase. Alternatively, mRNA can be reverse
10 transcribed into cDNA and a suitable label incorporated during cDNA synthesis.

Fragmentation of these labelled molecules can then precede hybridisation to the targeting
5 polynucleotides prior to capture on the generic array of the invention. As with conventional
differential expression studies using gene chips, different fluorescent labels (for example
15 Cy3(green) or Cy5(red)-labelled deoxyuridine triphosphate) can be used on different test
samples (i.e. induced versus un-induced) to enable direct comparison of gene expression
levels in the two samples on the same array. The relative fluorescence intensity of each fluor
20 at each array element (capture location) provides a measurement of the relative abundance of
the respective RNA in the two cell populations.

With current differential expression studies utilising oligonucleotide arrays, because of
25 the differences in hybridisation properties between short oligonucleotide probes, each target
gene must be represented by several oligonucleotides (typically 20 or more) on the chip. In
15 addition, a partner control oligonucleotide identical to each oligonucleotide, except for one of
the central nucleotides, is included on the array to serve as an internal control for
30 hybridisation sensitivity. Thus, whereas cDNA arrays only require each gene to be
represented by a single hybridisation partner on the array, with the oligonucleotide arrays,
each test gene must be represented by at least 40 distinct oligonucleotides each at a different
35 20 position on the array.

The use of many, for example 5-80, preferably, 10-20, 15-25, 20-30, 25-35, 35-50
distinct targeting polynucleotides per target gene (each range being a separate and
40 independent embodiment of the invention), each complementary to different regions of a
particular target gene, and each having the identical tail sequence for capture by a unique
25 capture oligonucleotide on the array, obviates the need for having many distinct
oligonucleotides at different locations on the array. Moreover, because each of the capture
45 oligonucleotides possess the same or substantially the same T_m , approximately equivalent
capture onto the solid support is expected. This means that the generic array and method of
the invention should be particularly suitable for differential expression studies where
50 30 quantitative analyses are desired. Quantitative analyses in current differential expression
studies are limited because of the different hybridisation stabilities of each capture:target

duplex sequence. Some sequences will bind more efficiently under a given set of hybridisation conditions than others, hampering precise quantitative analyses. This situation does not arise with the microarray of the present invention because all the capture oligonucleotides on the array possess the same or substantially the same T_m .

Thus according to a further aspect of the invention there is provided the use of the generic microarray, targeting polynucleotides and method of the invention in determining the expression levels of gene(s) from a sample.

A suitable sample might be a tissue sample, for example a biopsy or bodily fluid, such as blood, sample, or a cell sample, for example epithelial or buccal cells, or a cultured cell or cell line such as a mammalian cell or cell line, or a bacterial or yeast cell. Alternatively, it may be from a whole organism, such as *Arabidopsis thaliana*. Any sample containing one or a plurality of different genes is suitable.

Although preferred, the use of numerous distinct targeting polynucleotides each capable of binding to a different region of a particular gene, so as to overcome the different hybridisation properties problem identified above that short oligonucleotides probes have, need not be restricted to use with arrays comprising oligonucleotides that have substantially the same T_m .

Thus, according to another aspect there is provided a method for quantifying the expression level of a gene comprising:

(i) converting mRNA from a test sample into cDNA;

(ii) optionally, fragmenting said newly synthesised cDNA into appropriate length nucleic acid fragments;

(iii) contacting the cDNA with a plurality of targeting polynucleotide molecules under suitable conditions to allow hybridisation between substantially complementary sequences to occur, each polynucleotide molecule comprising a unique 3' portion substantially complementary to a unique region of the cDNA, a 5' tail portion complementary to one of a group of pre-selected oligonucleotides that are attached at pre-defined positions to a solid support, and optionally a spacer moiety interposed between said 3' and 5' portions;

(iv) contacting the components from step (iii) with a substrate on which is immobilised at pre-determined positions a plurality of capture oligonucleotide sequences each complementary to one or other of the 5' tail portions of the targeting polynucleotides so as to

allow the tailed cDNA/targeting polynucleotide duplex molecules to bind to their complementary capture oligonucleotide on the substrate; and

(v) detecting the amount of bound cDNA/targeting polynucleotide duplex at each position on the substrate.

According to a preferred embodiment of this particular aspect, unhybridised targeting polynucleotides are removed from the reaction mixture after step (iii). In another preferred embodiment, the sub-set of targeting polynucleotides directed to a specific gene all possess the same 5' tail portion sequence so that all targeting polynucleotide/cDNA duplex molecules formed can be captured at the same location (by the same oligonucleotide) on the support (array). In another embodiment, the method is used to determine expression levels of various genes in a test sample, each gene capable of being detected by a different sub-set of targeting polynucleotides and addressed to distinct positions on the support. In another embodiment, the cDNA generated in step (i) is detectably labelled. In another embodiment the gene or each gene to be detected, as represented by cDNA molecules produced in step (i), is detected by between 5 and 80 distinct polynucleotides that bind at distinct parts of the gene.

According to a further aspect of the invention there is provided, a method for identifying the differential expression of each of a plurality of genes in a first cell type with respect to expression of the same genes in a second cell type, said method comprising:

(i) isolating mRNA from each cell type and converting said mRNA into cDNA with incorporation of a different fluorescent label into the newly synthesised cDNA for each cell type;

(ii) optionally, fragmenting said newly synthesised cDNA into appropriate length nucleic acid fragments;

(iii) contacting said labelled nucleic acid with a plurality of targeting polynucleotide molecules under suitable conditions to enable hybridisation between substantially complementary sequences to occur, each polynucleotide molecule comprising a unique 3' portion substantially complementary to a unique target nucleic acid sequence which may be present in a sample, a 5' tail portion complementary to one of a group of pre-selected oligonucleotides that each possess substantially the same melting temperature (T_m) and are attached at pre-defined positions to a solid support, and optionally a spacer moiety interposed between said 3' portion and said 5' portion,

(iv) detectably hybridising the hybridised products from step (iii) to a solid surface on which is immobilised at pre-determined positions a plurality of oligonucleotide sequences complementary to one or other of the 5' tail portions of the targeting polynucleotides; and

(v) examining the solid support by fluorescence under fluorescence excitation

conditions to detect the bound nucleic acid from each cell type, whereby the amount of labelled nucleic acid from each cell type at each particular location on the solid surface can be detected on the basis of the different fluorescence emission colour produced by the different labels incorporated.

According to a further aspect of the invention there is provided a method for identifying the differential expression of each of a plurality of genes in a first cell type with respect to expression of the same genes in a second cell type, said method comprising:

(i) isolating mRNA from each cell type and converting said mRNA into cDNA with incorporation of a different fluorescent label into the newly synthesised cDNA for each cell type;

(ii) optionally, fragmenting said newly synthesised cDNA into appropriate length nucleic acid fragments;

(iii) contacting said labelled nucleic acid with a plurality of targeting polynucleotide molecules under suitable conditions to effect hybridisation between substantially complementary sequences, each polynucleotide molecule comprising a unique 3' portion substantially complementary to a unique target nucleic acid sequence which may be present in a sample, a 5' tail portion complementary to one of a group of pre-selected oligonucleotides that each possess substantially the same melting temperature (T_m) and are attached at pre-defined positions to a solid support, and optionally a spacer moiety interposed between said 3' and 5' portions;

(iv) contacting the hybridised products from step (iii) to a solid surface on which is immobilised at pre-determined positions a plurality of oligonucleotide sequences complementary to one or other of the 5' tail portions of the targeting polynucleotides; and,

(v) examining the solid support by fluorescence under fluorescence excitation

conditions to detect the bound nucleic acid from each cell type, whereby the amount of labelled nucleic acid from each cell type at each particular location on

the solid surface can be detected on the basis of the different fluorescence emission colour produced by the different labels incorporated.

In a preferred embodiment for differential expression studies, each target gene is detected by a plurality of targeting polynucleotides that bind at distinct parts of the target gene. In a more preferred embodiment, there are between 5 and 80, preferably about 10-20, 15-25, 20-30, 25-35, 35-50 distinct targeting oligonucleotides per target gene. Each range being a separate and independent embodiment of the invention. In another preferred embodiment, each of the targeting polynucleotide for a particular gene possesses an identical single stranded oligonucleotide tail portion capable of capturing the target:polynucleotide hybrid molecule onto a solid support at a pre-defined position. In another embodiment of the invention the identical gene detection products from each cell line are captured by different oligonucleotides on the array. For example, sequence location 200-230 of gene X isolated from normal tissue sample is captured at position A whereas sequence location 200-230 of gene X isolated from tumour tissue is captured at position B. Then sequence location 350-380 of gene X isolated from normal tissue sample can either also be captured at location A (to pool all the results for one gene from one cell type at one site) or at its own unique location C. Similarly, sequence location 350-380 of gene X isolated from tumour tissue can either be captured at position B or position D. Although not essential, it is preferred that the nucleotide sequence of each of the capture portions of the targeting polynucleotides and complementary sequences on the capture oligonucleotides on the solid support have substantially the same T_m .

In order to facilitate more accurate quantitative analysis, hybridisation conditions are adopted to ensure maximum annealing of the targeting polynucleotides to their target sequences. This may be effected by pooling together those targeting polynucleotides whose target binding sequence possesses on binding to its target approximately the same T_m as the others in the pool. More preferably, the target binding portion of each targeting polynucleotide in a particular pool is of the same nucleotide length and has the same G-C content as the others in the pool. According to a preferred embodiment therefore, each pool of targeting polynucleotides is hybridised to a portion of the test nucleic acid sample under optimum conditions for hybrid formation with their respective target sequences. The hybridisation reactions from each pool of targeting polynucleotides are then pooled together.

Following this, capture of the target bound sequences onto the solid support is effected using hybridisation conditions adapted according to the particular T_m of the capture duplexes.

For whatever application, hybridisation conditions chosen are designed to be as close as possible to the T_m of the duplexes. The concentration of salt in the hybridisation solution used is particularly significant. At 1M NaCl, G:C base pairs are more stable than A:T base pairs. Similarly, double stranded oligonucleotides with a higher G-C content have a higher T_m than those of the same length but with a higher A-T content. If slight differences, i.e. single nucleotide differences, amongst the target nucleic acids need to be distinguished, establishing optimum hybridisation conditions is important, particularly, when the hybridisable length of the oligonucleotides is small (< approximately 30-mers). Where, because of the diverse composition of the target sequences, there is a broad range of T_m , either a less than optimum compromise set of hybridisation conditions could be adopted, or conditions could be manipulated so as to diminish the T_m dependence on nucleotide composition by using chaotropic hybridisation solutions. This can be effected, for example, by incorporation into the hybridisation solution of a tertiary or quaternary amide.

Tetramethylammoniumchloride (TMACl) is particularly suitable when used at concentrations of between 2M and 5.5M. A preferred concentration range being 3M - 4M. Compared to the presence of 1M NaCl in the hybridisation solution, use of up to 5M TMACl can enhance hybridisation specificity by up to 40-fold. A preferred means of ensuring maximum hybrid formation despite there being a range of T_m due to target sequence composition, is to divide the population of targeting polynucleotides into groups according to their optimum T_m , and then to undertake separate hybridisation reactions using sub-groups of pooled targeting polynucleotides that are grouped according to the T_m of the targeting polynucleotide:target sequence hybrid portion. Each hybridisation can then be carried out under optimum hybridisation conditions for the particular group of targeting polynucleotides. In this manner, optimum hybridisation conditions can be adopted which will ensure approximately equivalent duplex formation. This may be of particular importance if quantitative analysis is required.

The products from the different hybridisation reactions can then be pooled ready for capture hybridisation to the solid support (Reaction B, see below). An example of a suitable hybridisation solution involving oligonucleotides of between 15 and 50 nucleotides is: 3M

TMACl, 0.01M sodium phosphate (pH 6.8), 1mM EDTA (pH 7.6), 0.5% SDS, 100 µg/ml denatured, fragmented salmon sperm DNA and 0.1% dried skimmed milk (i.e. Marvel™).

Use of the generic microarray and targeting polynucleotides of the invention requires two hybridisation reactions to be undertaken. One (A) involves hybrid formation between the targeting polynucleotides and the target nucleic acid in the test sample ("the wet reaction").

The other (B) involves hybrid formation between the targeting polynucleotides and the capture oligonucleotides bound to the solid support. Depending on the type of study undertaken, the hybridisations can be carried out in either order or together, although it is preferred that the wet reaction A is carried out prior to reaction B.

With differential expression studies it is preferred that hybridisation A be carried out under conditions that ensure maximal hybridisation of the targeting polynucleotides to target sequence. In general, expression monitoring experiments require long overnight hybridisations with low stringencies (higher salt concentrations, and lower temperatures) in order to allow hybrid formation between the target nucleic acids and probes that have different stabilities. This also enhances annealing of low copy number sequences. This "wet reaction" can therefore be carried out first in order to allow maximum annealing. Capture of the hybrid molecules from the "wet reaction" can then be effected using greater hybridisation stringencies (at lower salt concentrations and higher temperatures) over shorter time periods (i.e. 1 - 3 hours). The optimum hybridisation conditions can however, be determined from the expected T_m of the capture duplex molecules.

This invention is concerned with a novel microarray of universal use comprising a plurality of oligonucleotides, each possessing substantially the same T_m , attached at pre-defined positions to a solid support. The design and construction of solid support is well known in the art. Essentially, any conceivable solid substrate may be employed in the invention. A suitable substrate is a material having a rigid or semi-rigid surface, generally insoluble in a solvent of interest such as water. Specific suitable substrates are glass, plastics, polymers, polysaccharides, resins, metal, silica or silica-based material, nylon or nitrocellulose filters, and the like. The solid support may comprise a single sheet of a suitable material such as glass, silicon or plastic so that the pre-selected oligonucleotides are positioned at pre-defined sites based on each oligonucleotide having a distinct and distinguishable set of x,y co-ordinates. Alternatively the solid support may comprise a set of

beads of a suitable material such as glass or plastic so that the pre-selected oligonucleotides are positioned at pre-defined sites based on each oligonucleotide residing on a distinct bead.

In a preferred embodiment the substrate and/or its surface will be flat glass or single-crystal silicon. Suitable examples of existing laboratory materials that can be utilised are glass

microscope slides and microtitre (such as 96-well) plates. The surface of the substrate will preferably contain reactive groups such as carboxyl, amino, hydroxyl, or the like. A

polycationic polymer such as polylysine is particularly useful. Most preferably, with fluorescence detection, the surface is non-fluorescent at the wavelength that the analysis is to be performed. The surface of the substrate is also preferably provided with a layer of cross-

linking groups to assist attachment of the oligonucleotides to the support. These cross-linking groups will preferably be of sufficient length to permit the oligonucleotides attached to interact freely with their binding partners in solution. Crosslinking groups may be selected from any suitable class of compounds, for example, aryl acetylenes, ethylene glycol oligomers containing 2-1 monomer units, diamines, diacids, amino acids, and the like. The cross-linking groups may be attached by a variety of methods which are readily apparent to the person skilled in the art. For example, by esterification or amidation reactions of an activated ester of the linking group with a reactive hydroxyl or amine group on the free end of the cross-linking group.

The detection of specific interactions may be performed by detecting the positions where the labelled target sequences are attached to the array. Radiolabelled probes can be detected using conventional autoradiography techniques. Use of scanning autoradiography with a digitised scanner and suitable software for analysing the results is preferred. Where the label is a fluorescent label, the apparatus described, e.g in International Publication No. WO 90/15070, US Patent No. 5, 143,854 or US Patent No. 5,744,305 may be advantageously applied. Indeed, most array formats use fluorescent readouts to detect labelled capture:target duplex formation. Laser confocal fluorescence microscopy is another technique routinely in use (M.J.Kozal et al., Nature Medicine. 2:753-759, 1996). Mass spectrometry may also be used to detect oligonucleotides bound to a DNA array (Little DP et al, Analytical Chemistry. 69(22):4540-4546, 1997). Whatever the reporter system used, sophisticated gadgetry and software may be required in order to interpret large numbers of readouts into meaningful data

(such as described, for example, in US Patent No. 5,800,992 or International Publication No. WO 90/04652).

Once a particular sequence has, or group of sequences have, been hybridised to the microarray and the pattern of hybridisation analysed, the microarray can be treated to remove the bound sequences in preparation for reuse of the microarray by exposure to a second or subsequent set of target sequences. In order to do this the hybrid duplexes are disrupted and the solid support matrix treated in order to remove all traces of the original target. To effect this, the matrix may be treated with various detergents or solvents to which the substrate, the oligonucleotides and the linkages to the substrate are inert. This treatment may involve an elevated temperature treatment, treatment with organic or inorganic solvents, modifications in pH, and other means for disrupting specific interactions. Examples of methods that could be used are: (1) Washing the array with 50 mM sodium hydroxide to disrupt base pairing by high pH. (2) Washing the array with pure water and at high temperature (e.g. > 80°C) to disrupt base pairing by high stringency. (3) Addition of oligonucleotide sequences complementary to the tail sequences (and identical to the chip sequences) to disrupt base pairing by exchange with the sequences in free solution. Other methods for disrupting duplex formation are well known in the art (see for example Sambrook et al. *ibid*). Because the microarray of the invention is not a custom chip, but rather a generic chip which interacts with specific custom targeting oligonucleotides, once the microarray has been cleaned, it can be reused in any appropriate procedure and is not limited to reuse in the particular procedure used before. The discriminatory ability lies with the "wet reaction" involving the target nucleic acids with the custom targeting polynucleotides that co-operate with the generic microarray of the invention.

According to a further aspect of the invention there is provided a kit for detecting the presence or absence of one or more target nucleic acid sequences contained in a sample, which kit comprises:-

- (i) a plurality of polynucleotides, each polynucleotide comprising a unique 3' portion substantially complementary to a unique target nucleic acid sequence which may be present in a sample, a 5' portion complementary to one of a group of pre-selected oligonucleotides that each possess substantially the same melting temperature (T_m) and are attached at pre-defined positions to a solid support, and optionally a spacer moiety interposed between said 3' portion and said 5' portion; and

5 (ii) a solid support having immobilised thereon a plurality of pre-selected oligonucleotides at
pre-defined positionally distinct sites, characterised in that the composition of each of the
10 oligonucleotides is such that they all have substantially the same melting temperature (T_m)
when annealed to their complementary sequence, each capture oligonucleotide having a
5 sequence complementary to a 5' portion of one of the polynucleotides in (i).

15 In a preferred embodiment the kit also contains some or all four different nucleoside
triphosphates and/or an agent for polymerisation of the nucleoside triphosphates and/or
instructions for use. In accordance with the general principle of the invention, the targeting
portion of the polynucleotides may be acting as hybridisation probes or
20 amplification/detection primers. In a preferred embodiment the kit comprises a set of at least
two primers for each target sequence, the terminal nucleotide of at least one primer being
complementary to a suspected variant nucleotide associated with a known genetic disorder
and at least one of the other primers being a companion primer as described hereinbefore. The
25 kit may therefore comprise sets of oligonucleotide primers, each set targeting different alleles
15 at a specific loci. In a further embodiment, the polynucleotide molecules referred to in (i) are
ARMS primers with non-amplifiable tails as described hereinbefore. In a further embodiment
30 the solid support is a microscope slide or microtitre plate, such as a 96-well plate. Such kits
may also comprise control DNA and control primers or probes, and the like.

The invention will now be further illustrated by the following non-limiting examples.

35 20 The examples refer to the following figures, in which:

Figure 1 - Illustrates the use of quenching oligonucleotides for measuring primer binding.

40 Figure 2a - Results from Experiment 1, 84-ARMS primer multiplex on 1% p53 codon 175
CAC admixture template and wild-type; OD 405nm mutant (ODm) and wild-type (ODw) plot
for the 11 test ARMS primers and one control primer.

25 Figure 2b - Results from Experiment 1, (ODm/ODw)-1 ratio of absorbance (405nm) on p53
wild-type and mutant admixture for 1% 175 CAC.

45 Figure 3a - Results from Experiment 1, 84-ARMS primer multiplex on 5% p53 codon 175
CAC admixture template and wild-type; OD 405nm mutant (ODm) and wild-type (ODw) plot
for the 11 test ARMS primers and one control primer.

50 Figure 3b - Results from Experiment 1, (ODm/ODw)-1 ratio of absorbance (405nm) on p53
wild-type and mutant admixture for 5% 175 CAC.

Figure 4a - Results from Experiment 2, 84-ARMS primer multiplex on 1% p53 codon 175 CAC admixture template and wild-type; OD 405nm mutant (ODm) and wild-type (ODw) plot for the 17 test ARMS primers and two control primer.

Figure 4b - Results from Experiment 2, (ODm/ODw)-1 ratio of absorbance (405nm) on p53 wild-type and mutant admixture for 10% 175 CAC.

Example 1

Multiplex tailed ARMS assay to detect p53 mutations.

Many potential mutation sites in p53 have been identified (P.Hainaut et al, Nucleic Acids Research. 26(1):205-213, 1998).

80 ARMS primers were designed for the specific detection of some of the mutations in exons 5-8 of the p53 tumour suppressor gene (Table 3 lists the 80 codon positions and specific mutations for which ARMS primers were designed and prepared). Uniquely identifying non-amplifiable tails (with T_m s in the range of 53°C to 58°C) with hexaethylene glycol links between the primer and the tail sequences were added to 19 of these ARMS primers (marked * in Table 3). The 80 ARMS primers were then multiplexed together with 2 reverse primers designed to give PCR products with the ARMS primers specific for mutations in exons 5&6 and 8 respectively. Tailed primer sets which act as control primers for the detection of p53 exons 5&6 and exon 8 sequence were also included.

Table 3.

List of potential p53 mutations on which the ARMS primers were prepared.

132 CAG*	132 AGG	135 TAC	141 TAC	151 TCC	151 ACC*
152 CTG	154 GTC	156 CCC*	157 TTC*	158 CTC*	158 CAC
159 GAC*	159 GTC	161 ACC	163 TGC	173 ATG	173 TTG*
175 CAC*	176 TTC*	177 CGC*	179 CGT	179 TAT	192 TAG
193 CGT	195 ACC	196 TGA	205 TGT	213 TGA	220 TGT*
228 AAC	234 TGC	237 ATA	238 TAT	241 TTC	242 TTC
244 TGC	245 TGC	245 GAC	245 AGC	245 CGC	245 GTC
245 GCC	248 CTG	248 CAG	248 TGG	248 GGG	248 CCG
249AGC	249AGT	249 ACG	249 ATG	249 GGG	249 AAG

258 AAA	258 GGA	266 AGA	266 GAA	266 TGA	266 GTA
272 ATG	273 CCT*	273 CTT*	273 CAT*	273 TGT*	273 AGT
273 GGT	275 TAT	278 CTT	278 TCT	280 ACA*	282 TGG
282 CAG	282 CCG	282 CTG	282 GGG	285 AAG*	286 AAA*
298 TAG*	306 TGA				

* - denotes the mutant codon for which a tailed ARMS primer was prepared.

Templates containing mutations in the p53 gene were prepared by primer directed mutagenesis (see Higachi et al. NAR. 16:7350-7367, 1988). This gave templates of 500 - 800 bp containing the mutation of interest. Wild type templates were prepared by PCR amplification of wild-type DNA to give the corresponding 500 - 800 bp fragments.

All templates were quantified relatively by real time analysis on an ABI Prism 7700 using a quantitative PCR reaction. Quantitated cassettes (mutant synthetic templates prepared by site directed mutagenesis) were then used to prepare wild-type/mutant admixtures.

Oligonucleotides of precise complementary sequence to the 19 tail sequences were synthesised with 3' biotin moieties. These capture sequences were bound to the wells of a streptavidin coated microtitre plate (one capture sequence per well).

Reaction conditions: Each ARMS primer was present at 50 nM concentration, the reverse primers were present at 500mM concentration and wild type dNTPs at 50 μ M each. Fluorescein-dUTP was also included at 0.5 μ M. The buffer was 50 mM KCl, 10 mM Tris, 1.2 mM $MgCl_2$ at pH 8.3. 4 Units of AmpliTaq Gold™ were used per amplification. 10^5 copies of template were added. Cycling conditions were 94°C for 20 minutes then 35 cycles of (94°C for 1 minute, 60°C for 1 minute). In each experiment, three parallel experiments were run using (a) wild type template, (b) mutant/wild-type admixture template and (c) a no-template control.

Following amplification, the PCR products were divided between the capture wells of the microtitre plate. Hybridisation between the PCR products and the capture oligos took place overnight at 55°C in 3M TMAC, 1M Tris (pH 7.5), 0.5M EDTA, 0.01% Triton-X-100, 0.1mg/ml herring sperm DNA. Unbound products were then washed off (2 washes in phosphate buffered saline (PBS)). The PCR products were detected by ELISA detection of

incorporated fluorescein-dUTP using an anti-fluorescein-alkaline phosphatase antibody-enzyme conjugate. Colour development was by addition of *p*-nitrophenyl phosphate and the OD 405 was determined after 30 minutes.

For each primer being examined the following ODs were obtained: (i) the mutant template termed OD_m; (ii) the wild-type template termed OD_w; and, (iii) the no-template control. The no-template control ODs were subtracted from OD_m and OD_w to give background corrected values. OD_m, OD_w values and the (OD_m/OD_w - 1) ratio were then plotted.

Experiment 1 - Detection of a single point mutation at codon position 175 of p53 present as template at a concentration of 1% or 5%.

Admixtures were prepared between template containing p53 mutant codon 175 CAC and wild-type template with the mutant sequence present at 1% and 5% of the total.

Specific tailed ARMS primer used to detect p53 175 CAC mutation:

5'-GCTTTATGTCCACAGATTC*ATACACAGCACATGACGGAGGTTGTGAGCCA-3'
SEQ ID NO.1 represents the 5' tail portion; SEQ ID No. 2 represents the 3' targeting portion.
The * denotes the HEG group.

Specific reverse primer used with the above ARMS primer:

5'-ACCCGGAGGGCCACTGACAAC-3' (SEQ ID No. 3)

For each admixture three separate amplifications (using the multiplex of 80 mutant ARMS primers and 2 control primers, 19 of which had tails so that they could be captured-see Table 3) were carried out on: (a) the admixture; (b) wild-type template; and, (c) no-template control. The amplification products were then each added to a separate array consisting of a microtitre dish with 11 capture oligos for a subset of the primers plus 1 capture oligo for the exon 5&6 control reaction immobilised thereon.

The OD_m and OD_w values with the relevant no-template control values subtracted are shown in figures 2a and 3a. The figures show that the primer for 175 CAC gives a signal on the mutant template (bars) which is higher than the one obtained with wild-type template

(diamonds). The size of the signal is dependant on the amount of mutant template present in the substrate and is therefore greater for the 5% mutant template than for the 1% mutant template.

The ability of the primer for 175 CAC to differentially detect low levels of mutant sequence can be also seen by calculating the (ODm/ODw-1) ratios (see Figures 2b and 3b). From these values it can be clearly seen that only the primer for 175 CAC demonstrates a significantly higher OD on the mutant template than on the wild-type template.

Careful examination of the OD405nm data and the (ODm/ODw)-1 plots permits one to distinguish between primers which are selectively detecting mutant sequence and those that are giving unselective amplification from wild-type as well as mutant template. Experiment 2 illustrates this more fully.

Experiment 2

Detection of a single point mutation at codon position 175 of p53 present as template at a concentration of 10%.

An admixture was prepared between template containing p53 mutant codon 175 CAC at 10% in a wild type background. As in experiment 1, three separate amplifications were carried out on: (a) the admixture; (b) wild-type template; and, (c) no-template control. The products of the amplifications were then each added to a separate array consisting of 17 capture oligos for the primers plus 2 capture oligos for exon 5, 6 and exon 8 control reactions. The ODm and ODw values with the relevant no-template control values subtracted are shown in Figure 4a. This figure shows that the primer for 175 CAC has given a signal on the mutant template (bars) which is far higher than the one obtained with wild-type template (diamonds). It can also be seen that the 220 TGT mutation has a propensity to prime and give detectable product with wild-type template as well as on the mutant template. That this primer is not erroneously detecting mutant sequence can be seen by calculating the (ODm/ODw-1) ratios (see Figure 4b) in which case it can be clearly seen that only the primer for 175 CAC is giving a higher OD on the mutant template than on the wild-type template.

Summary:

Example 1 demonstrates the use of ARMS for the sensitive detection of under-represented sequences in combination with the use of non-amplifiable tails and oligonucleotide arrays to provide a method for the large scale multiplex analysis of polymorphisms in gene sequences.

The use of ARMS in solution phase permits the more sensitive detection of gene variation than can be achieved with solid phase allele specific oligonucleotide (ASO) hybridisation.

The use of non-amplifiable tails and oligonucleotide arrays presents a more generic and widely applicable technique than can be achieved with ASO arrays which must be individually designed on a target to target basis. In this way a maximally efficient mutation detection system is produced because each component used in the process is suited to the process it is required to carry out. Mutation detection can be carried out in solution phase using ARMS and DNA arrays used for separating complex mixtures of oligonucleotide sequences.

The use of non-amplifiable tails and oligonucleotide arrays presents a simpler hybridisation technique than can be achieved with ASO arrays. With ASO arrays all of the probe to targets hybridisations require to be carried out under the same conditions including the same temperature and buffer. These conditions may not be ideal for many of the probe to target hybridisations which require to be performed. With generic arrays and non-amplifiable tails a single set of unified hybridisation conditions can be pre-selected which permit all probe to target hybridisations to be carried out under the same optimal conditions because all probe to target hybridisations can be selected to occur between sequences of substantially the same T_m and GC content.

The use of non-amplifiable tails and oligonucleotide arrays also presents a more cost effective way of screening for mutations than can be achieved with ASO arrays. The manufacture of the array used in the screening process is cheaper than is the case with specific ASO arrays because:

1. Depending on its use, the generic array will likely require far fewer capture sequences for the analysis of each variant in the gene of interest than is possible with a specific ASO array and therefore, is far simpler and cheaper to manufacture.

- 5
2. Once the array has been designed it may be used for the analysis of any gene target. The costs of designing and developing new arrays for new gene targets is avoided.
- 10 3. With one array being used for the analysis of all gene targets economy of scale can be realised during manufacture compared to the situation where smaller manufacturing runs
- 5 are undertaken to produce a multitude of specific arrays.

Example 2

Design of suitable oligonucleotides with substantially the same T_m .

15 Oligonucleotide sequences of substantially the same T_m can conveniently be generated by use of a spreadsheet computer program incorporating a random number generator. By way

20 of example the following Visual Basic macro, when run in Microsoft Excell™, will generate random sequences of between 10 and thirty bases in length. The T_m of these bases is then calculated using the simple algorithm $T_m = [2 * (\#A \text{ or } T) + 4 * (\#G \text{ or } C)]$ (i.e. each A or T base pair adds 2°C to the T_m while a G or a C adds 4°C). The program then sorts the

25 sequences in order of increasing T_m . In this way oligos of substantially the same T_m can be selected as candidate sequences for use as tails. It should be understood that the use of this

15 T_m algorithm is illustrative only and that any convenient algorithm could be used.

Macro:

Option Explicit

Sub probe()

35 20 'Declare arrays

Dim well

Dim number

Dim repeat

40 Dim percent

25 'get number of sequences to generate

Let number = Application.InputBox("Enter number of random sequences to generate")

45 'redeclare arrays

ReDim NextCell(30)

ReDim Character(30)

30 ReDim NoBases(number)

50 ReDim NoGC(number)

- 41 -

5

ReDim PercentGC(number)

ReDim Tm(number)

10

Dim limit

Dim total

5 'Generate Probe Sequences

For repeat = 1 To number

15

'determine sequence length

Range("BB1").Select

ActiveCell.FormulaR1C1 = "=ABS(RAND())"

20

10 Range("BB1").Select

Let limit = (ActiveCell * 20) + 10

'generate sequence

For well = 1 To limit

25

Range("A1").Select

15 ActiveCell.Offset(repeat, well).FormulaR1C1 = "=ABS(RAND())"

Range("A1").Select

30

ActiveCell.Offset(repeat, well).Select

Selection.Copy

Range("A1").Select

35

20 ActiveCell.Offset(repeat, well).Select

Selection.PasteSpecial Paste:=xlValues, Operation:=xlNone, _

SkipBlanks:=False, Transpose:=False

Next well

40

'convert to bases, detect G and C, total Tm

25 Let NoBases(repeat) = 0

Let NoGC(repeat) = 0

45

Let Tm(repeat) = 0

For well = 1 To limit

Range("A1").Select

50

30 Let NextCell(well) = ActiveCell.Offset(repeat, well)

If (NextCell(well) < 0.25 And NextCell(well) > 0#) Then

55

5

Let Character(well) = "A"

Let NoBases(repeat) = NoBases(repeat) + 1

10

Let Tm(repeat) = Tm(repeat) + 2

End If

5 Let NextCell(well) = ActiveCell.Offset(repeat, well)

If (NextCell(well) < 0.5 And NextCell(well) > 0.25) Then

15

Let Character(well) = "C"

Let NoBases(repeat) = NoBases(repeat) + 1

Let NoGC(repeat) = NoGC(repeat) + 1

20

10 Let Tm(repeat) = Tm(repeat) + 4

End If

Let NextCell(well) = ActiveCell.Offset(repeat, well)

If (NextCell(well) < 0.75 And NextCell(well) > 0.5) Then

25

Let Character(well) = "G"

15 Let NoBases(repeat) = NoBases(repeat) + 1

Let NoGC(repeat) = NoGC(repeat) + 1

30

Let Tm(repeat) = Tm(repeat) + 4

End If

Let NextCell(well) = ActiveCell.Offset(repeat, well)

35

20 If NextCell(well) > 0.75 Then

Let Character(well) = "T"

Let NoBases(repeat) = NoBases(repeat) + 1

Let Tm(repeat) = Tm(repeat) + 2

40

End If

25 Next well

Range("A1").Select

45

For well = 1 To limit

ActiveCell.Offset(repeat, well).FormulaR1C1 = Character(well)

Next well

50

30 Range("A1").Select

ActiveCell.Offset(repeat, 0).FormulaR1C1 = repeat

55

5

'calculate %GC

Let PercentGC(repeat) = (NoGC(repeat) / NoBases(repeat)) * 100

10

Next repeat

'output calculations

5 Range("AG1").Select

For repeat = 1 To number

15

ActiveCell.Offset(repeat, 0).FormulaR1C1 = NoBases(repeat)

Next repeat

Range("AH1").Select

20

10 For repeat = 1 To number

ActiveCell.Offset(repeat, 0).FormulaR1C1 = PercentGC(repeat)

Next repeat

25

Range("AI1").Select

For repeat = 1 To number

15 ActiveCell.Offset(repeat, 0).FormulaR1C1 = Tm(repeat)

Next repeat

30

Columns("A:AF").Select

Selection.ColumnWidth = 4

ActiveWindow.SmallScroll ToRight:=17

35

20 Columns("AH:AH").Select

Selection.NumberFormat = "0.0"

Range("AG1").Select

ActiveCell.FormulaR1C1 = "# bases"

40

Range("AH1").Select

25 ActiveCell.FormulaR1C1 = "% GC"

Range("AI1").Select

45

ActiveCell.FormulaR1C1 = "Tm °C"

Range("A1").Select

ActiveWindow.ScrollColumn = 1

50

30 Columns("A:AI").Select

Selection.Sort Key1:=Range("AI2"), Order1:=xlAscending, Header:= _

55

- 44 -

```

xlYes, OrderCustom:=1, MatchCase:=False, Orientation:= _
xlTopToBottom
Range("A1").Select
End Sub

```

The design and choice of suitable tail sequences with substantially the same T_m can of course also be carried out manually using the simple algorithm $T_m = [2 * (\#A \text{ or } T) + 4 * (\#G \text{ or } C)]$.

10 Example 3.

A suitable format for differential expression studies.

cDNA is prepared from mRNA purified from two types of tissue representing normal and altered cells. The altered cells may have been treated differently to the normal cells prior to mRNA purification. Examples of 'different treatment' include starving the cells of a metabolite or metabolites, stimulating them with a specific metabolite such as a growth factor or treating them with a drug or hormone. Alternatively, different cell conditions might exist already, i.e. normal Vs tumour.

Typically, reverse transcription from an oligo-dT primer is carried out with incorporation of fluorescent labels into the cDNA prepared. Often one label such as Cy-3 is used to label the cDNA from the normal tissue and another label such as Cy-5 is used to label the cDNA from the treated tissue. The cDNA population is optionally fragmented by sonication or mechanical shearing (i.e. by passage through a 19G needle). Targeting polynucleotides are added to the cDNA mixture and hybridisation permitted to occur, for example, under the following hybridisation condition: labelled cDNA is resuspended in 10 ml of 3.5 x SSC containing 4mg of poly dA DNA, 2.5 mg *E. coli* tRNA, 4mg human Cot1 DNA and 1:10 10% SDS. Hybridisation is carried out at 62°C for 3hours.

To facilitate quantitative analysis and ensure efficient target binding and identification, each cDNA is targeted by a number of distinct targeting polynucleotides each capable of hybridising to a different region of the cDNA, but all possessing the same tail sequence to facilitate capture at the same pre-determined location on the microarray. By way of example, each cDNA is targeted by 20 or more distinct targeting polynucleotides. As described above,

the targeting polynucleotides comprise two principal domains, the first domain is complementary to a distinct region of one of the cDNAs in the sample mixture and the second domain (tail portion) is complementary to one of the capture oligonucleotides on the DNA array. If the range of T_m between the target sequences and their complementary sequences on the targeting polynucleotides is wide, it may be preferable to group the targeting polynucleotides into pools of substantially the same T_m . In this way, separate sample:targeting polynucleotide hybridisations can be carried out under the optimum hybridisation conditions for each pool. All the pooled reaction products can then be mixed prior to the capture hybridisation. Once hybridisation between the cDNA and the targeting polynucleotides is substantially complete, the mixture is added to the surface of the oligonucleotide microarray under suitable conditions to allow hybridisation between the targeting polynucleotide tail portion to occur. Hybridisation is carried out at 62°C for 1-3 hours in a suitable volume of hybridisation solution such as 10ml of 6x SSC, 0.1% SDS and 0.25% dried skimmed milk (Marvel™) in a suitable enclosed vessel. A proprietary hybridisation apparatus such as model HB-1 (Techne Ltd) provides reproducible conditions for the experiment. On completion of hybridisation the microarray is subjected to a stringency wash (such as in 2xSSC, 0.2% SDS, then 0.2xSSC) and the array surface is subjected to fluorescence. Fluorescent output from the two dyes is captured and stored as separate channels. The intensity of the two data sets is normalised by reference to a common housekeeping gene whose expression is considered to be invariant in all tissues. There are many such genes but one example is GAPDH.

Having normalised the data, the differences in intensity at each point on the microarray is measured. Up or down regulation of genes in the treated tissues would be seen as increases or decreases respectively in the intensity of the Cy-5 signal compared to the intensity of the same array spot in the Cy-3 channel.

Claims

5

10

15

20

25

30

35

40

45

50

55

CLAIMS

1. A solid support having immobilised thereon a plurality of oligonucleotides at pre-defined positionally distinct sites, characterised in that the sequence of each oligonucleotide that binds to its complementary sequence has substantially the same melting temperature (T_m).
2. A support as claimed in claim 1 wherein 90% of the oligonucleotides on the support possess T_m s within 4°C of each other.
3. A support as claimed in claim 1 or 2 wherein the oligonucleotides are detectably labelled.
4. A support as claimed in any of the preceding claims which comprises at least 50, particularly at least 500 and more particularly at least 5000, distinct oligonucleotides on the support.
5. A support as claimed in any of claims 1 to 4 wherein each oligonucleotide is non-complementary with genomic DNA and non complementary with each other.
6. A method for identifying the presence or absence of one or more test nucleic acid sequences in a sample, comprising:
 - (i) contacting a nucleic acid containing sample with a plurality of single stranded targeting polynucleotide molecules under suitable hybridisation conditions to ensure hybrid formation between the targeting nucleotide portion of the targeting polynucleotide molecule and its complementary target nucleic acid sequence in the sample, each of said targeting polynucleotide molecules possessing, in addition to the targeting nucleotide portion, a unique single-stranded oligonucleotide tail sequence complementary to a unique capture oligonucleotide sequence attached to a solid support, characterised in that substantially all of the oligonucleotides possess substantially the same T_m when bound to their complementary sequence on the tail;
 - (ii) optionally separating the unhybridised targeting polynucleotide molecules from the hybrid molecules;
 - (iii) contacting the population of hybrid molecules to a solid support having attached thereon at pre-defined locations unique capture oligonucleotides, each capture oligonucleotide being complementary to one or other of the oligonucleotide tail

sequences on the targeting molecules, under suitable conditions to ensure capture of each of the hybrid molecules to the solid support; and

(iv) determining the presence or absence of the captured hybrid molecules at each of the pre-defined locations on the solid support.

7 A method as claimed in claim 6 wherein the targeting polynucleotides are amplification primers and an amplification reaction is performed after step (i).

8. A method as claimed in claim 7 wherein the primers are amplification refractory mutation system (ARMS) primers.

9. A method as claimed in claim 7 or claim 8 wherein each primer is used in conjunction with a second companion primer to amplify the target region of interest.

10. A method for identifying the differential expression of each of a plurality of genes in a first cell type with respect to expression of the same genes in a second cell type comprising:

(i) isolating mRNA from each cell type and converting said mRNA into cDNA with incorporation of a detectable label into the newly synthesised cDNA;

(ii) optionally, fragmenting said newly synthesised cDNA into appropriate length nucleic acid fragments;

(iii) contacting said labelled nucleic acid with a plurality of targeting polynucleotide molecules under suitable conditions to effect hybridisation between substantially complementary sequences, each polynucleotide molecule comprising a unique 3' portion substantially complementary to a unique target nucleic acid sequence which may be present in a sample, a 5' tail portion complementary to one of a group of pre-selected oligonucleotides that each possess substantially the same melting temperature (T_m) and are attached at pre-defined positions to a solid support, and optionally a spacer moiety interposed between said 3' and 5' portions;

(iv) contacting the hybridised products from step (iii) to a solid surface on which is immobilised at pre-determined positions a plurality of oligonucleotide sequences complementary to one or other of the 5' tail portions of the targeting polynucleotides; and,

(v) determining the expression level of each gene in each cell type according to the amount of label detected.

5

10

15

20

25

30

35

40

25

45

50

55

11. A method as claimed in claim 10 wherein each target gene is detected by a plurality of targeting polynucleotides that bind at distinct parts of the target gene.

12. A method as claimed in claim 10 or claim 11 wherein there are between 5 and 80 distinct targeting oligonucleotides per target gene.

13. A method as claimed in claim 10, 11 or 12 wherein step (iii) is carried out as separate reactions between the target cDNAs and separate pools of targeting polynucleotides, the cDNA target binding sequences of the polynucleotides in each pool possessing approximately the same T_m as the others in the pool; the hybridisation reactions from each pool of targeting polynucleotides are then pooled together.

14. A method for quantifying the expression level of a gene comprising:

(i) converting mRNA from a test sample into cDNA;

(ii) optionally, fragmenting said newly synthesised cDNA into appropriate length nucleic acid fragments;

(iii) contacting the cDNA with a plurality of targeting polynucleotide molecules under suitable conditions to allow hybridisation between substantially complementary sequences to occur, each polynucleotide molecule comprising a unique 3' portion substantially complementary to a unique region of the cDNA, a 5' tail portion complementary to one of a group of pre-selected oligonucleotides that are attached at pre-defined positions to a solid support, and optionally a spacer moiety interposed between said 3' and 5' portions;

(iv) contacting the components from step (iii) with a substrate on which is immobilised at pre-determined positions a plurality of capture oligonucleotide sequences each complementary to one or other of the 5' tail portions of the targeting polynucleotides so as to allow the tailed cDNA/targeting polynucleotide duplex molecules to bind to their complementary capture oligonucleotide on the substrate; and

(v) detecting the amount of bound cDNA/targeting polynucleotide duplex at each position on the substrate.

15. A kit for detecting the presence or absence of one or more target nucleic acid sequences contained in a sample, which kit comprises:-

(i) a plurality of polynucleotides, each polynucleotide comprising a unique 3' portion substantially complementary to a unique target nucleic acid sequence which may be


present in a sample, a 5' portion complementary to one of a group of pre-selected oligonucleotides that each possess substantially the same melting temperature (T_m) and are attached at pre-defined positions to a solid support, and optionally a spacer moiety interposed between said 3' portion and said 5' portion; and

- (ii) a solid support having immobilised thereon a plurality of pre-selected oligonucleotides at pre-defined positionally distinct sites, characterised in that the composition of each of the oligonucleotides is such that they all have substantially the same melting temperature (T_m) when annealed to their complementary sequence, each capture oligonucleotide having a sequence complementary to a 5' portion of one of the polynucleotides in (i).


16. A kit as claimed in claim 15 also comprising one or more of:

- (i) nucleotide triphosphates;
- (ii) a polymerisation agent;
- (iii) control DNA; and,
- (iv) instructions for use.

DNA array with fluorescently labelled capture oligonucleotides:



Addition of short quencher oligonucleotides to quench array:



addition of purified amplification products to array:




Figure 1. Use of quenching oligonucleotides (Q) for measuring primer binding.
F represents fluorescent label attached to capture oligonucleotide.





Figure 2a. Experiment 1. ODm (bars) and ODw (line)







Figure 3a. Experiment 1. ODm (bars) and ODw (line)






Figure 4a Experiment 2. ODm (bars) and ODw (line)




Figure 4b Experiment 2. (ODm/ODw)-1

- 1 -
SEQUENCE LISTING

<110> ZENECA Limited

5 <120> NOVEL MATRIX

<130> LDSG/PHM70478/WO

<140> 9902970.4

10 <141> 1999-02-11

<150> 9902970.4

<151> 1999-02-11

15 <160> 3

<170> PatentIn Ver. 2.1

<210> 1

20 <211> 20

<212> DNA

<213> Artificial Sequence

<220>

25 <223> Description of Artificial Sequence: Single
Stranded Capture Sequence.

<400> 1

30 gctttatgtc cacagatttc 20

<210> 2

<211> 31

<212> DNA

35 <213> Homo sapiens

<400> 2

atacacagca catgacggag gttgtgagcc a 31

40

<210> 3

<211> 21

WO 00/47767

PCT/GB00/00357

- 2 -

<212> DNA

<213> Homo sapiens

<400> 3

5 acccgaggagg ccactgacaa c

21

INTERNATIONAL SEARCH REPORT

Inter. Int. Application No.

PCT/GB 00/00357

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 31256 A (BLOK HERMAN ;BARANY GEORGE (US); KEMPE MARIA (US); ZIRVI MONIB (US) 28 August 1997 (1997-08-28) see whole doc. esp. claim 13	1-5
X	EP 0 799 897 A (AFFYMETRIX INC) 8 October 1997 (1997-10-08) see whole doc., esp. claims 10,11	1-5
Y	GB 2 312 747 A (ZENECA LTD) 5 November 1997 (1997-11-05) the whole document	6-16
Y	EP 0 416 817 A (ICI PLC) 13 March 1991 (1991-03-13) cited in the application see whole doc. esp. claims	6-16
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

31 May 2000

Date of mailing of the international search report

07/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Müller, F

1

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/00357

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 25563 A (HOPE CITY ; WALLACE ROBERT BRUCE (US)) 23 December 1993 (1993-12-23) see whole doc. esp. claims and figures	6-16
A	OLD J M: "DETECTION OF MUTATIONS BY THE AMPLIFICATION REFRACTORY MUTATION SYSTEM (ARMS)" METHODS IN MOLECULAR BIOLOGY, US, HUMANA PRESS INC., CLIFTON, NJ, vol. 9, 1991, pages 77-84, XP000775640 the whole document	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/00357

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9731256 A	28-08-1997	AU 2799797 A CA 2244891 A EP 0920440 A	10-09-1997 28-08-1997 09-06-1999
EP 0799897 A	08-10-1997	NONE	
GB 2312747 A	05-11-1997	AU 2704997 A EP 0896630 A WO 9742345 A	26-11-1997 17-02-1999 13-11-1997
EP 0416817 A	13-03-1991	AT 144290 T AU 622349 B AU 6118490 A DE 69028891 D DE 69028891 T GB 2235689 A, B JP 3272686 A NZ 235015 A US 5525494 A	15-11-1996 02-04-1992 14-03-1991 21-11-1996 13-03-1997 13-03-1991 04-12-1991 26-03-1992 11-06-1996
WO 9325563 A	23-12-1993	CA 2115342 A AU 674127 B AU 2251192 A EP 0607151 A JP 6509946 T US 5981176 A	23-12-1993 12-12-1996 04-01-1994 27-07-1994 10-11-1994 09-11-1999